Comparison of the differences between domestic and imported versions of macitentan and analysis of differences in efficacy

Macitentan (Macitentan) is an oral dual endothelin receptor antagonist (ERA), mainly used to treat pulmonary arterial hypertension (PAH) by blocking endothelin receptor antagonists. Cortin-1 acts on ETA and ETB receptors, reducing pulmonary artery pressure, improving cardiopulmonary function and delaying disease progression. Currently, there are two versions of imported original drugs and domestic generic drugs on the market, and patients are often concerned about their differences and comparison of efficacy when choosing.

From the perspective of drug ingredients and dosage, the main active ingredients and standard dosage of imported and domestic macitentan are basically the same, and both are taken orally once a day10mg. Pharmacokinetic studies show that there is little difference between the two in terms of in vivo absorption, peak plasma concentration and half-life, indicating that domestic drugs can theoretically achieve similar blood concentration maintenance and action time as imported drugs.

In terms of efficacy, both clinical studies and real-world data show that domestically produced macitentan and imported original drugs have similar performance in improving 6 minute walking distance (6MWD), reducing pulmonary artery pressure, and improving cardiac function indicators. Some studies have shown that in long-term treatment, domestic drugs are not significantly different from imported drugs in terms of patient tolerance, cardiac function improvement, and incidence of side effects. The main adverse reactions include headache, peripheral edema, and anemia, most of which are mild to moderate and can be managed through monitoring and dose adjustment.

However, the difference is mainly in terms of price and accessibility. Imported drugs are more expensive and difficult for some patients to maintain long-term, while domestic drugs are more affordable and can improve long-term compliance. In addition, some hospitals and medical insurance policies make it more convenient for domestic drugs to be reimbursed, making it easier for patients to obtain continuous treatment. On the premise of ensuring efficacy and safety, domestically produced macitentan provides an economically feasible and effective alternative for patients with pulmonary arterial hypertension, while also helping to improve patients' long-term medication compliance.

Reference materials:https://www.drugs.com/